Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1(+) Chemoresistant Lung Cancer Cells

PURPOSE: Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non–small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte-independent, therapeutic activity of aPD-1 against...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotolo, Ramona, Leuci, Valeria, Donini, Chiara, Galvagno, Federica, Massa, Annamaria, De Santis, Maria Chiara, Peirone, Serena, Medico, Giovanni, Sanlorenzo, Martina, Vujic, Igor, Gammaitoni, Loretta, Basiricò, Marco, Righi, Luisella, Riganti, Chiara, Salaroglio, Iris Chiara, Napoli, Francesca, Tabbò, Fabrizio, Mariniello, Annapaola, Vigna, Elisa, Modica, Chiara, D’Ambrosio, Lorenzo, Grignani, Giovanni, Taulli, Riccardo, Hirsch, Emilio, Cereda, Matteo, Aglietta, Massimo, Scagliotti, Giorgio Vittorio, Novello, Silvia, Bironzo, Paolo, Sangiolo, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890136/
https://www.ncbi.nlm.nih.gov/pubmed/36165915
http://dx.doi.org/10.1158/1078-0432.CCR-22-0761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890136/
https://www.ncbi.nlm.nih.gov/pubmed/36165915
http://dx.doi.org/10.1158/1078-0432.CCR-22-0761

Ejemplares similares